BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totalling 179,200 shares, a growth of 28.7% from the August 31st total of 139,200 shares. Based on an average trading volume of 270,600 shares, the days-to-cover ratio is presently 0.7 days.
BioLineRx Stock Performance
Shares of NASDAQ:BLRX traded down $0.01 during midday trading on Friday, reaching $0.62. 145,924 shares of the company’s stock traded hands, compared to its average volume of 333,238. The company has a market cap of $49.56 million, a price-to-earnings ratio of -0.82 and a beta of 1.46. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61. BioLineRx has a one year low of $0.51 and a one year high of $2.03. The stock has a 50 day moving average of $0.69 and a 200 day moving average of $0.72.
BioLineRx (NASDAQ:BLRX – Get Free Report) last posted its quarterly earnings data on Thursday, August 15th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The firm had revenue of $5.39 million for the quarter, compared to analysts’ expectations of $3.93 million. As a group, equities research analysts anticipate that BioLineRx will post -0.25 EPS for the current fiscal year.
Institutional Trading of BioLineRx
Wall Street Analysts Forecast Growth
Separately, StockNews.com raised BioLineRx from a “sell” rating to a “hold” rating in a report on Monday, June 3rd.
Get Our Latest Research Report on BLRX
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Featured Articles
- Five stocks we like better than BioLineRx
- What is Forex and How Does it Work?
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- CarMax’s Impressive Rally: What Investors Should Watch Next
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.